Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Immunochemotherapy in Relapsed iNHL
NCT02626455Phase 3Terminated
- Sponsor
- Bayer
- Start
- Jan 2016
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 35
01
Overview
A Phase 3 trial of copanlisib in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Bayer. Started Jan 2016; status: terminated.
02
Drugs
copanlisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT02626455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626455.